448 related articles for article (PubMed ID: 33205006)
1. Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin-activated RNA methylation.
Roy KR; Uddin MB; Roy SC; Hill RA; Marshall J; Li YT; Chamcheu JC; Lu H; Liu YY
FASEB Bioadv; 2020 Nov; 2(11):653-667. PubMed ID: 33205006
[TBL] [Abstract][Full Text] [Related]
2. An N
Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
[TBL] [Abstract][Full Text] [Related]
3. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
5. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.
Liu YY; Hill RA; Li YT
Adv Cancer Res; 2013; 117():59-89. PubMed ID: 23290777
[TBL] [Abstract][Full Text] [Related]
6. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
[TBL] [Abstract][Full Text] [Related]
7. UDP-glucose ceramide glucosyltransferase activates AKT, promoted proliferation, and doxorubicin resistance in breast cancer cells.
Wegner MS; Schömel N; Gruber L; Örtel SB; Kjellberg MA; Mattjus P; Kurz J; Trautmann S; Peng B; Wegner M; Kaulich M; Ahrends R; Geisslinger G; Grösch S
Cell Mol Life Sci; 2018 Sep; 75(18):3393-3410. PubMed ID: 29549423
[TBL] [Abstract][Full Text] [Related]
8. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.
Liu YY; Patwardhan GA; Bhinge K; Gupta V; Gu X; Jazwinski SM
Cancer Res; 2011 Mar; 71(6):2276-85. PubMed ID: 21278235
[TBL] [Abstract][Full Text] [Related]
9. Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells.
Gupta V; Bhinge KN; Hosain SB; Xiong K; Gu X; Shi R; Ho MY; Khoo KH; Li SC; Li YT; Ambudkar SV; Jazwinski SM; Liu YY
J Biol Chem; 2012 Oct; 287(44):37195-205. PubMed ID: 22936806
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine-phosphorylation and activation of glucosylceramide synthase by v-Src: Its role in survival of HeLa cells against ceramide.
Honda T; Motoyoshi K; Kasahara J; Yamagata K; Takahashi H; Nakamura H; Murayama T
Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Jan; 1866(1):158817. PubMed ID: 32980536
[TBL] [Abstract][Full Text] [Related]
11. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
[TBL] [Abstract][Full Text] [Related]
12. A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer.
Madigan JP; Robey RW; Poprawski JE; Huang H; Clarke CJ; Gottesman MM; Cabot MC; Rosenberg DW
Exp Cell Res; 2020 Mar; 388(2):111860. PubMed ID: 31972222
[TBL] [Abstract][Full Text] [Related]
13. Glucosylceramide synthase and glycosphingolipid synthesis.
Ichikawa S; Hirabayashi Y
Trends Cell Biol; 1998 May; 8(5):198-202. PubMed ID: 9695839
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
15. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
[TBL] [Abstract][Full Text] [Related]
16. Glucose availability and glycolytic metabolism dictate glycosphingolipid levels.
Stathem M; Marimuthu S; O'Neal J; Rathmell JC; Chesney JA; Beverly LJ; Siskind LJ
J Cell Biochem; 2015 Jan; 116(1):67-80. PubMed ID: 25145677
[TBL] [Abstract][Full Text] [Related]
17. Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma.
Kang N; Wang Y; Guo S; Ou Y; Wang G; Chen J; Li D; Zhan Q
BMC Cell Biol; 2018 Aug; 19(1):16. PubMed ID: 30126368
[TBL] [Abstract][Full Text] [Related]
18. Hotspot mutant p53-R273H inhibits KLF6 expression to promote cell migration and tumor metastasis.
Sun S; Chen H; Sun L; Wang M; Wu X; Xiao ZJ
Cell Death Dis; 2020 Jul; 11(7):595. PubMed ID: 32733026
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of neutral glycosphingolipid synthesis upon long term inhibition of ceramide synthesis by fumonisin B1.
Meivar-Levy I; Futerman AH
J Biol Chem; 1999 Feb; 274(8):4607-12. PubMed ID: 9988695
[TBL] [Abstract][Full Text] [Related]
20. Blockade of Glycosphingolipid Synthesis Inhibits Cell Cycle and Spheroid Growth of Colon Cancer Cells In Vitro and Experimental Colon Cancer Incidence In Vivo.
Jennemann R; Volz M; Bestvater F; Schmidt C; Richter K; Kaden S; Müthing J; Gröne HJ; Sandhoff R
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]